Business Information
The group's principal activity is to discover, develop and market novel, synthetic and small molecule compounds for the treatment of cardiovascular, vascular and related inflammatory diseases. The research and development programs of the group are focused on the treatment and prevention of interrelated diseases of the vascular endothelium. The group presently has development programs such as thrombosis, vasospasm program, vascular inflammation program and vascular remodeling. The group operates in the United States and Germany. On 23-Apr-2003, the group acquired icos-Texas biotechnology l.p.
|
|
Name |
Title
|
Email
|
| James Willerson | Dir., Chmn. - Scientific Advisory Board | N/A | | John Pietruski | Chmn. | N/A | | Gordon Busenbark | CFO | N/A | | Richard Dixon | Dir., Sr. VP - Research, Chief Scientific Officer | N/A | | Ann Tanabe | VP - Corporate Communications, Investor Relations | Available
|
|
|
Year |
Sales |
Net Income |
| 2006 | 18,995 | (109,283) | | 2005 | 14,006 | (74,877) | | 2004 | 13,778 | (54,660)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
